Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis

Journal of Rheumatology

Volumn 40, Issue 6, 2013, Pages 850-858

  Zhang, Xuli Jerry ^a   Bonner, Ashley ^b   Hudson, Marie ^c   Baron, Murray ^c   Pope, Janet ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Dysphagia; Gastroesophageal reflux disease; Interstitial lung disease; Pulmonary fibrosis; Scleroderma; Systemic sclerosis

Indexed keywords

DNA TOPOISOMERASE;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DYSPHAGIA; ESOPHAGUS DILATATION; ESOPHAGUS DISEASE; FEMALE; FORCED VITAL CAPACITY; GASTRIC DYSMOTILITY; GASTROESOPHAGEAL REFLUX; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SATIETY; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY;

DYSPHAGIA; GASTROESOPHAGEAL REFLUX DISEASE; INTERSTITIAL LUNG DISEASE; PULMONARY FIBROSIS; SCLERODERMA; SYSTEMIC SCLEROSIS;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; VITAL CAPACITY;

EID: 84878650140     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120705     Document Type: Article

References (40)

1. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
2. Hassoun PM. Lung involvement in systemic sclerosis. Presse Med 2011;40:e3-17.
3. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-9.
4. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-5.
5. Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203.
6. Akesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: A comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol 1989;28:281-6.
7. Turner R, Lipshutz W, Miller W, Rittenberg G, Schumacher HR, Cohen S. Esophageal dysfunction in collagen disease. Am J Med Sci 1973;265:191-9.
8. Behr J, Furst DE. Pulmonary function tests. Rheumatology 2008;47 Suppl 5:v65-7.
9. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: Demographic, clinical, and serologic features and survival in 1, 012 Italian patients. Medicine 2002;81:139-53.
10. Kane GC, Varga J, Conant EF, Spirn PW, Jimenez S, Fish JE. Lung involvement in systemic sclerosis (scleroderma): Relation to classification based on extent of skin involvement or autoantibody status. Respir Med 1996;90:223-30.
11. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4.
12. Khimdas S, Hardin S, Bonner A, Zummer B, Baron M, Pope J, et al. Associations with digital ulcers in a large cohort of systemic sclerosis: Results from the Canadian Scleroderma Research Group registry. Arthritis Care Res 2011;63:142-9.
13. Assassi S, Sharif R, Lasky RE, McNearney TA, Estrada-Y-Martin RM, Draeger H, et al. Predictors of interstitial lung disease in early systemic sclerosis: A prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010;12:R166.
14. Plastiras SC, Karadimitrakis SP, Ziakas PD, Viachoyiannopoulos PG, Moutsopoulos HM, Tzelepis GE. Scleroderma lung: Initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006;55:598-602.
15. Ebert EC. Esophageal disease in scleroderma. J Clin Gastroenterol 2006;40:769-75.
16. Lock G, Pfeifer M, Straub RH, Zeuner M, Lang B, Scholmerich J, et al. Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. Am J Gastroenterol 1998;93:341-5.
17. Marie I, Dominique S, Levesque H, Ducrotte P, Denis P, Hellot MF, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001;45:346-54.
18. Johnson DA, Drane WE, Curran J, Cattau EL Jr, Ciarleglio C, Khan A, et al. Pulmonary disease in progressive systemic sclerosis. A complication of gastroesophageal reflux and occult aspiration? Arch Intern Med 1989;149:589-93.
19. Marie I, Ducrotte P, Denis P, Hellot MF, Levesque H. Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther 2006;24:1593-601.
20. Gilson M, Zerkak D, Eipff J, Dusser D, Dinh-Xuan AT, Abitbol V, et al. Prognostic factors for lung function in systemic sclerosis: Prospective study of 105 cases. Eur Respir J 2010;35:112-7.
21. Abu-Shakra M, Guillemin F, Lee P. Gastrointestinal manifestations of systemic sclerosis. Semin Arthritis Rheum 1994;24:29-39.
22. Marie I, Levesque H, Ducrotte P, Hellot MF, Benichou J, Cailleux N, et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol 2001;96:77-83.
23. Sjogren RW. Gastrointestinal features of scleroderma. Curr Opin Rheumatol 1996;8:569-75.
24. Walker J, Baron M, Pope J, Hudson M, Fritzler M, Nadashkevitz O, et al. The development of systemic sclerosis classification criteria. Clin Rheumatol 2007;26:1401-9.
25. Rondinelli RD, Genovese E, Brigham CR. Guides to the evaluation of permanent impairment. 6th ed. Chicago: American Medical Association; 2008.
26. Owens GR, Fino GJ, Herbert DL, Steen VD, Medsger TA, Pennock BE, et al. Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. Chest 1983;84:546-50.
27. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
28. Ing AJ. Interstitial lung disease and gastroesophageal reflux. Am J Med 2001;Suppl 8A:41S-44S.
29. Mays EE, Dubois JJ, Hamilton GB. Pulmonary fibrosis associated with tracheobronchial aspiration. A study of the frequency of hiatal hernia and gastroesophageal reflux in interstitial pulmonary fibrosis of obscure etiology. Chest 1976;69:512-55.
30. Appel JZ 3rd, Lee SM, Hartwig MG, Hsieh CC, Cantu E 3rd, Yoon Y, et al. Characterization of the innate immune response to chronic aspiration in a novel rodent model. Respir Res 2007;8:87.
31. Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008;31:1357-67.
32. Cohen S, Fisher R, Lipshutz W, Turner R, Myers A, Schumacher R. The pathogenesis of esophageal dysfunction in scleroderma and Raynaud's disease. J Clin Invest 1972;51:2663-8.
33. Denis P, Ducrotte P, Pasquis P, Lefrancois R. Esophageal motility and pulmonary function in progressive systemic sclerosis. Respiration 1981;42:21-4.
34. Kahrilas PJ, Dodds WJ, Hogan WJ. Effect of peristaltic dysfunction on esophageal volume clearance. Gastroenterology 1988;94:73-80.
35. Christmann BB, Wells AU, Capelozzi VL, Silver RM. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: Clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum 2010;40:241-9.
36. Savarino E, Bazzica M, Zentilin P, Pohl D, Parodi A, Cittadini G, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: A study using pH-impedance monitoring. Am J Respir Crit Care Med 2009;179:408-13.
37. de Souza RB, Borges CT, Capelozzi VL, Parra ER, Jatene FB, Kavakama J, et al. Centrilobular fibrosis: An underrecognized pattern in systemic sclerosis. Respiration 2009;77:389-97.
38. Troshinsky MB, Kane GC, Varga J, Cater JR, Fish JE, Jimenez SA, et al. Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Intern Med 1994;121:6-10.
39. Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006;27:136-42.
40. Khanna D, Hays RD, Maranian P, Seibold JR, Imoens A, Mayes MD, et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009;61:1257-63.